射频消融治疗甲状腺乳头状癌的研究进展

doi:10.13481/j.1671-587x.20190346

[1] 潘明, 陈闯, 牛志昊,等. 射频消融治疗甲状腺乳头状癌的临床进展[J]. 中国地方病防治杂志, 2015(3):182-183.
[2] HAUGEN B R. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer:What is new and what has changed?[J].Cancer,2017,123(3):372-381.
[3] CHANG H, KIM SM, CHUN KW, et al.Clinicopathologic features of solid variant papillary thyroid cancer[J]. ANZ J Surg,2014,84(5):380-382.
[4] KIM J H, YOO W S, PARK Y J, et al. Efficacy and safety of radiofrequency ablation for treatment of locally recurrent thyroid cancers smaller than 2 cm[J]. Radiology, 2015,276(3):909-918.
[5] GARBEROGLIO R, ALIBERTI C, APPETECCHIA M, et al. Radiofrequency ablation for thyroid nodules:which indications? The first Italian opinion statement[J]. J Ultrasound, 2015, 18(4):423-430.
[6] 周茂胜, 常欣. 射频消融原理及应用[J]. 当代医学, 2009, 15(21):18-19.
[7] SHIN J E, BAEK J H, LEE J H. Radiofrequency and ethanol ablation for the treatment of recurrent thyroid cancers:Current status and challenges[J]. Current Opinion Oncol, 2012, 25(1):14-19.
[8] FRANZ A M, SEITEL A, BOPP N, et al. First clinical use of the EchoTrack guidance approach for radiofrequency ablation of thyroid gland nodules[J]. Int J Computer Assisted Radiol Surg, 2017, 12(6):931-940.
[9] 刘池拽, 邓建伟, 师天雄. RFA技术在甲状腺疾病中的临床进展[J]. 中华普通外科学文献:电子版, 2015(3):54-57.
[10] XIAOYIN T, DAN C, JIACHANG C, et al. Evaluation of the safety and efficacy of radiofrequency ablation for treating benign thyroid nodules[J]. J Cancer, 2017, 8(5):754-760.
[11] KIM J H, BAEK J H, SUNG J Y, et al. Radiofrequency ablation of low-risk small papillary thyroidcarcinoma:preliminary results for patients ineligible for surgery[J]. Int Hyperthermia, 2017, 33(2):8.
[12] GUAN Y, LUO Y, ZHANG Y, et al. Efficacy and safety of percutaneous ultrasound guided radiofrequency ablation for treating cervical metastatic lymph nodes from papillary thyroid carcinoma[J]. J Cancer Res Clin Oncol, 2017,143(8):1555-1562.
[13] KIM C, LEE J H, CHOI Y J, et al. Complications encountered in ultrasonography-guided radiofrequency ablation of benign thyroid nodules and recurrent thyroid cancers[J]. Eur Radiol, 2017, 27(8):3128-3137.
[14] 李建如, 罗渝昆, 李岩密,等. 超声引导下RFA治疗甲状腺微小乳头状癌的疗效分析[J]. 解放军医学院学报, 2016, 37(8):823-826.
[15] 刘晓岭, 黄靖, 孙德胜,等. 超声引导下RFA治疗甲状腺微小乳头状癌的临床体会[J]. 黑龙江医学, 2015(1):69-70.
[16] LONG B, LI L, YAO L, et al. Combined use of radioiodine therapy and radiofrequency ablation in treating postsurgical thyroid remnant of differentiated thyroid carcinoma[J]. J Cancer Res Therap, 2015, 11(Suppl 8):C244.
[17] MONCHIK J M, DONATINI G, IANNUCCILLI J, et al. Radiofrequency ablation and percutaneous ethanol injection treatment for recurrent local and distant well-differentiated thyroid carcinoma[J]. Ann Surg, 2006, 244(2):296-304.
[18] XU D, CHEN L, QIAN C, et al. Ultrasonography-guided percutaneous radiofrequency ablation for cervical lymph node metastasis from thyroid carcinoma[J]. J Cancer Res Therapeut, 2014, 10(7):144.
[19] 张丹琦,赵滨滨,张素冰. 针刺复合舒芬太尼麻醉在微创甲状腺RFA术中的应用[A]. 中国中西医结合麻醉学会[CSIA]年会暨第二届全国中西医结合麻醉学术研讨会、江苏省中西医结合学会麻醉专业委员会成立大会论文汇编[C]. 扬州:2015.
[20] ITO Y, MIYAUCHI A, KIHARA M, et al. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation[J]. Thyroid, 24(1):27-34.
[21] JEONG S Y, BAEK J H, CHOI Y J, et al.Radiofrequency ablation of primary thyroid carcinoma:efficacy according to the types of thyroid carcinoma[J]. Int J Hyperthermia, 2018,34(5):611-616.
[22] 董文武, 张浩, 张平,等. 甲状腺乳头状癌射频消融治疗后再手术5例临床分析[J]. 中国实用外科杂志, 2015, 35(6):653-655.
[23] YANG L, TANG H, LEE A M, et al. Risk of malignancy in symptomatic nodular goiter treated with radiofrequency ablation[J]. AJNR Am Neuroradiol, 2015, 37(1):E7.
[24] 田文, 王宇, 郗洪庆,等. 甲状腺疾病RFA治疗现状与争议[J]. 中国实用外科杂志, 2018,38(1):75-78.
[25] LIM H K, BAEK J H, LEE J H, et al. Efficacy and safety of radiofrequency ablation for treating locoregional recurrence from papillary thyroid cancer[J]. Eur Radiol, 2015, 25(1):163-170.
[26] ZHAO Q, TIAN G, KONG D. Meta-analysis of radiofrequency ablation for treating the local recurrence of thyroid cancers[J]. J Endocrinol Invest, 2016, 39(8):909-916.
[27] MAZZEO S, CERVELLI R, ELISEI R, et al. mRECIST criteria to assess recurrent thyroid carcinoma treatment response after radiofrequency ablation:a prospective study[J]. J Endocrinol Invest,2018,41(12):1389-1399.
[28] 广旸, 罗渝昆, 张艳,等. 超声引导下RFA治疗PTC颈部转移淋巴结的疗效评价[J]. 中国医学科学院学报, 2018(1),40(1):67-71.
[29] BAEK J H, NA D G, PARK H S. RE:Management of low-risk papillary thyroid microcarcinoma[J]. Korean J Radiol, 2017, 18(2):408-409.
[30] CAZZATO R L, BONICHON F, BUY X, et al. Over ten years of single-institution experience in percutaneous image-guided treatment of bone metastases from differentiated thyroid cancer[J]. Eur J Surg Oncol,2015,41(9):1247-1255.
[31] KIM M, KIM W G, PARK S, et al. Growth kinetics of macronodular lung metastases and survival in differentiated thyroid carcinoma[J]. Thyroid, 2017,27(7):915-922.
[32] MASSICOTTE M H, BRASSARD M, CLAUDE-DESROCHES M, et al. Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas:a retrospective study of the TUTHYREF network[J]. Eur J Endocrinol, 2014, 170(4):575-582.
[33] 隋洋, 吴凤林, 孙医学. 超声引导下RFA甲状腺结节的并发症与预防方法探讨[J]. 医学影像学杂志, 2014, 24(1):32-35.
[34] KIM J H, BAEK J H, SUNG J Y, et al. Radiofrequency ablation of low-risk small papillary thyroidcarcinoma:preliminary results for patients ineligible for surgery[J]. Int J Hyperthermia, 2017,33(2):212-219.
[35] 娄雪峰, 吴凤林, 纪莉,等. RFA高风险甲状腺结节避免喉返神经损伤的方法探讨[J]. 中国超声医学杂志, 2014, 30(7):577-580.
[36] BERNARDI S, LANZILOTTI V, PAPA G, et al.Full-thickness skin burn caused by radiofrequency ablation of a benign thyroid nodule[J]. Thyroid, 2016,26(1):183-184.
[37] 马建新, 杜大勇, 李运田. 甲状腺功能减退患者RFA术后出现意识模糊一例[J]. 中国心脏起搏与心电生理杂志, 2009, 23(3):268-268.
[38] ODDO S, SPINA B, VELLONE V G, et al. A case of thyroid cancer on the track of the radiofrequency electrode 30 months after percutaneous ablation[J]. J Endocrinol Invest, 2017,40(1):101-102.
[39] LEE C U, KIM S J, SUNG J Y, et al. Needle track tumor seeding after radiofrequency ablation of a thyroid tumor[J]. Japan J Radiol, 2014, 32(11):661-663.

Research progress in radiofrequency ablation in treatment of papillary thyroid carcinoma

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Comments

Recommended 0

[1]	. Research progress in thyroid cancer related genes and their applications in clinical diagnosis [J]. Journal of Jilin University Medicine Edition, 2018, 44(04): 880-885.
[2]	ZHAO Zhiyan, SHENG Jindong, LIU Baoguo. Risk factors of malignant thyroid neoplasms and papillary thyroid cancer level Ⅵ lymph node metastasis [J]. Journal of Jilin University Medicine Edition, 2017, 43(02): 334-338.
[3]	. Progress research on relationship between Ki-67 and BRAF gene mutation and invasiveness of papillary thyroid carcinoma [J]. Journal of Jilin University Medicine Edition, 2016, 42(06): 1259-1262.
[4]	ZHAO Min-xue，LI Bai-wen，ZHU Lin，YE Hong-shan，TIAN Xiao-feng，WEI Liang，CAO Hong. Detection of miR-21 expression levels in carcinoma tissue and serum of patients with papillary thyroid carcinoma and its significance [J]. Journal of Jilin University Medicine Edition, 2014, 40(06): 1237-1240.
[5]	SUN Qin-nuan，LI Dong-mei，YU Hui-ling，MA Hong-xi. Expressions of inflammatory factors in thyroid papillary carcinoma tissue and their clinical significances [J]. Journal of Jilin University Medicine Edition, 2014, 40(06): 1261-1265.
[6]	WU Wen-fang,QIU Jin-xu,LU Li-min,YANG Dong-yan . Characteristics of ultrasound imaging of thyroid papillary carcinoma complicated with cervical lymph node tuberculosis [J]. Journal of Jilin University Medicine Edition, 2014, 40(04): 895-897.
[7]	WANG Hai-ying,JIN Mei-shan,ZHANG Xin-mu,TIAN Zhuang,ZOU Ya-bin,GAO Jing-na,DUAN Xiu-mei,WANG Yin-ping. Expressions of survivin,galectin-3 and TPO in papillary  thyroid microcarcinoma tissue and their clinical significances  [J]. Journal of Jilin University Medicine Edition, 2014, 40(01): 150-153.
[8]	. Advanced research on relationship between iodine intake and thyriod cancer [J]. Journal of Jilin University Medicine Edition, 2013, 39(4): 847-850.
[9]	WANG Chong，LIU Xiao-li，SHI Jie-ping，WU Yan-hua，WANG Shi-bing，YU Ya-qin，SUN Hui. Association analysis between RET gene polymorphism and papillary thyroid carcinoma [J]. Journal of Jilin University Medicine Edition, 2013, 39(2): 322-325.
[10]	HE Meng-zi,ZHAO Yin-long,LIU Xiao-dong,MA Shu-mei,LIU Xin. Screening and prediction of differential expression miRNA and their target genes in papillary thyroid carcinoma tissue [J]. Journal of Jilin University Medicine Edition, 2013, 39(1): 99-103.
[11]	SUN Ya-dong, ZHANG Jing-bin, YANG Le,MA Yan, JIANG Chun-hao,DI Jun . Expression \|of EG-1 in human thyroid papillary carcinoma tissue detected by real-time quantitative  PCR and its clinical significance [J]. J4, 2012, 38(5): 981-984.
[12]	LI Xin-bai,MENG Xian-ying,WANG Guang-yi,ZHANG Qiang,LI Qun. Inhibitory effects of celecoxib on \|expressions of VEGF  \|and　 MMP-9 in human medullary thyroid TT cells and their mechanisms [J]. J4, 2012, 38(3): 543-546.
[13]	NIU Chun-bo\|WANG Li-ping\|WANG Xue-mei\|CUI Ya-nan\|JIA Fei-yong\|ZHANG Guang. Application of Galectin-3 and CK19 expressions in pathological diagnosis of \|thyroid puncture biopsy [J]. J4, 2012, 38(2): 312-314.
[14]	LI Xin-bai,LIU Huan-qiu,MENG Xian-ying,YUAN Tong,HAN Wei,TONG Ti,MA Hai-chun. Application of dexmedetomidine combined with fibreoptic bronchoscope for tracheal intubation in difficult airways caused by huge goiter [J]. J4, 2012, 38(2): 328-332.
[15]	YU Peng,GONG Feng-ling,LIANG Yong-ping,WANG Rong-fu,ZHANG Jian-hua. Analysis on correlation of thyroglobulin with 131-iodine whole body scan in differentiated thyroid carcinoma patientsafter thyroid ablation [J]. J4, 2011, 37(4): 691-694.